Skip to main content
SpringerLink
Log in

Drug Interactions and Polypharmacy

  • Chapter
  • First Online:
Book cover Management of Lung Cancer in Older People

Abstract

Lung cancer is highly prevalent in senior adults. Older people are the greatest consumers of medications and healthcare resources in developed countries; this implies that patients are affected by different age-related conditions including one or more other serious chronic diseases, i.e., comorbidity, especially cardiovascular diseases, chronic obstruction pulmonary disease (COPD), or diabetes. Due to the presence of comorbidity, older adults are more likely to use an increased number of medications and at high risk for adverse drug events. Such condition is generally referred as “polypharmacy.” Cancer-related therapy, adding new medications for both active cancer treatment and supportive therapy, further increases the risk of polypharmacy. Older oncologic patients with multiple comorbidities are at risk for adverse drug events associated with polypharmacy and drug–drug interactions due to patients’ altered pharmacokinetic/pharmacodynamic status and the narrow therapeutic windows associated with antineoplastic agents. In clinical practice, it is difficult to separate the effects of cancer and its treatment or complications from the effects of comorbidity and polypharmacy. In response to this, geriatricians and oncologists have developed comprehensive geriatric assessment (CGA) tools for cancer patients. The CGA encompasses the evaluation of numerous clinical domains, including physical function, psycho-cognitive status, nutrition, social support, comorbidity, and in a minor percentage polypharmacy. CGA instruments are strongly recommended and predictive of mortality and morbidity for several chronic diseases and in different clinical settings. Cancer-specific CGA are currently being evaluated with the aim to individualize the treatment based on age-related conditions including comorbidity.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Janssen-Heijnen MLG, Maas HA, Houterman S, et al. Comorbidity in older surgical cancer patients: influence on patient care and outcome. Eur J Cancer. 2007;43:2179–93.

    Article  PubMed  Google Scholar 

  2. Extermann M, Chen H, Cantor AB, et al. Predictors of tolerance to chemotherapy in older cancer patients: a prospective pilot study. Eur J Cancer. 2002;38:1466–73.

    Article  PubMed  CAS  Google Scholar 

  3. Repetto L, Fratino L, Audisio RA, et al. Comprehensive geriatric assessment adds information to Eastern Cooperative Oncology Group performance status in elderly cancer patients: an Italian Group for Geriatric Oncology Study. J Clin Oncol. 2002;20:494–502.

    Article  PubMed  Google Scholar 

  4. Extermann M, Aapro M, Bernabei R, Task force on CGA of the International Society of Geriatric Oncology, et al. Use of the comprehensive geriatric assessment in older cancer patients: recommendations from the task force on CGA of the International Society of Geriatric Oncology (SIOG). Crit Rev Oncol Hematol. 2005;55:241–52.

    Article  PubMed  Google Scholar 

  5. Levy B, Kosteas J, Slade M, et al. Exclusion of elderly persons from health-risk behavior clinical trials. Prev Med. 2006;43:80–5.

    Article  PubMed  Google Scholar 

  6. Van Spall HG, Toren A, Kiss A, et al. Eligibility criteria of randomized controlled trials published in high-impact general medical journals: a systematic sampling review. JAMA. 2007;297:1233–40.

    Article  PubMed  Google Scholar 

  7. Flood KL, Carroll MB, Le CV, et al. Polypharmacy in hospitalized older adult cancer patients experience from a prospective, observational study of an oncology-acute care for elders unit. Am J Geriatr Pharmacother. 2009;7:151–8.

    Article  PubMed  Google Scholar 

  8. Lichtman SM, Boparai MK. Geriatric medication management: evaluation of pharmacist interventions and potentially inappropriate medication (PIM) use in older (≥65 years) cancer patients. J Clin Oncol. 2009;27(15S):484s (Abstr. 9507).

    Google Scholar 

  9. Sokol KC, Knudsen JF, Li MM. Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management. J Clin Pharm Ther. 2007;32:169–75.

    Article  PubMed  CAS  Google Scholar 

  10. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  11. Marengoni A, Rizzuto D, Wang H, et al. Patterns of chronic multimorbidity in the elderly population. J Am Geriatr Soc. 2009;57:225–30.

    Article  PubMed  Google Scholar 

  12. Yancik R. Cancer burden in the aged: an epidemiologic and demographic overview. Cancer. 1997;80:1273–83.

    Article  PubMed  CAS  Google Scholar 

  13. Extermann M. Measuring comorbidity in older cancer patients. Eur J Cancer. 2000;36:453–71.

    Article  PubMed  CAS  Google Scholar 

  14. Piccirillo JF, Tierney RM, Costas I, et al. Prognostic importance of comorbidity in a hospital based cancer registry. JAMA. 2004;291:2441–7.

    Article  PubMed  CAS  Google Scholar 

  15. Meyerhardt JA, Catalano PJ, Haller DG, et al. Impact of diabetes mellitus on outcomes in patients with colon cancer. J Clin Oncol. 2003;21:433–40.

    Article  PubMed  Google Scholar 

  16. Hughes KS, Schnaper LA, Berry D, et al. Lumpectomy plus tamoxifen with or without irradiation in women 70 years of age or older with early breast cancer. N Engl J Med. 2004;351:971–7.

    Article  PubMed  CAS  Google Scholar 

  17. Konety BR, Cowan JE, Carroll PR. Patterns of primary and secondary therapy for prostate cancer in elderly men: analysis of data from CaPSURE. J Urol. 2008;179:1797–803.

    Article  PubMed  Google Scholar 

  18. Yancik R, Wesley MN, Ries LAG, et al. Effect of age and comorbidity in postmenopausal breast cancer patients aged 55 years and older. JAMA. 2001;285:885–92.

    Article  PubMed  CAS  Google Scholar 

  19. Keating NL, Landrum MB, Klabunde CN, et al. Adjuvant chemotherapy for stage III colon cancer: Do physicians agree about the importance of patient age and comorbidity? J Clin Oncol. 2008;26:2532–7.

    Article  PubMed  Google Scholar 

  20. Blanco JAG, Toste IS, Alvarez RF, et al. Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing. 2008;37:715–8.

    Article  PubMed  Google Scholar 

  21. Aparicio T, Desrame J, Lecomte T, et al. Oxaliplatin- or irinotecan-based chemotherapy for metastatic colorectal cancer in the elderly. Br J Cancer. 2003;89(8):1439–44.

    Article  PubMed  CAS  Google Scholar 

  22. Asmis TR, Ding K, Seymour L, et al. Age and comorbidity as independent prognostic factors in the treatment of non-small-cell lung cancer: a review of National Cancer Institute of Canada Clinical Trials Group trials. J Clin Oncol. 2008;26:54–9.

    Article  PubMed  CAS  Google Scholar 

  23. Moscetti L, Nelli F, Padalino D, et al. Gemcitabine and cisplatin in the treatment of elderly patients with advanced non-small cell lung cancer: impact of comorbidities on safety and efficacy outcome. J Chemother. 2005;17:685–92.

    PubMed  CAS  Google Scholar 

  24. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment predict survival of elderly patients with advanced non small cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol. 2005;28:6865–72.

    Article  Google Scholar 

  25. Sawada S, Komori E, Nogami N, et al. Advanced age is not correlated with either short-term or long-term postoperative results in lung cancer patients in good clinical condition. Chest. 2005;128:1557–63.

    Article  PubMed  Google Scholar 

  26. Viktil KK, Blix HS, Moger TA, et al. Polypharmacy as commonly defined is an indicator of limited value in the assessment of drug-related problems. Br J Clin Pharmacol. 2007;63:187–95.

    Article  PubMed  Google Scholar 

  27. Maggiore RJ, Gross GP, Hurria A. Polypharmacy in older adults with cancer. Oncologist. 2010;15:507–22.

    Article  PubMed  CAS  Google Scholar 

  28. Jørgensen T, Johansson S, Kennerfalk A, et al. Prescription drug use, diagnoses, and healthcare utilization among the elderly. Ann Pharmacother. 2001;35:1004–9.

    Article  PubMed  Google Scholar 

  29. Onder G, Landi F, Liperoti R, et al. Impact of inappropriate drug use among hospitalized older adults. Eur J Clin Pharmacol. 2005;61:453–9.

    Article  PubMed  Google Scholar 

  30. Lichtman S. Pharmacokinetics and pharmacodynamics in the elderly. Clin Adv Hematol Oncol. 2007;5:181–2.

    PubMed  Google Scholar 

  31. Repetto L, Venturino A, Vercelli V, et al. Performance status and comorbidity in elderly cancer patients compared to a young neoplastic and an elderly non-neoplastic population. Cancer. 1998;82:760–5.

    Article  PubMed  CAS  Google Scholar 

  32. Riechelmann RP, Tannock IF, Wang L, et al. Potential drug interactions and duplicate prescriptions among cancer patients. J Natl Cancer Inst. 2007;99:592–600.

    Article  PubMed  Google Scholar 

  33. Hustey FM, Wallis N, Miller J. Inappropriate prescribing in an older ED population. Am J Emerg Med. 2007;25:804–7.

    Article  PubMed  Google Scholar 

  34. Hughes CM. Medication non-adherence in the elderly: how big is the problem? Drugs Aging. 2004;21:793–811.

    Article  PubMed  Google Scholar 

  35. Green JL, Hawley JN, Rask KJ. Is the number of prescribing physicians an independent risk factor for adverse drug events in an elderly outpatient population? Am J Geriatr Pharmacother. 2007;5:31–9.

    Article  PubMed  Google Scholar 

  36. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Do too many cooks spoil the broth? Multiple physician involvement n medical management of elderly patients and potentially inappropriate drug combinations. CMAJ. 1996;154:1177–84.

    PubMed  CAS  Google Scholar 

  37. Colt HG, Shapiro AP. Drug-induced illness as a cause for admission to a community hospital. J Am Geriatr Soc. 1989;37:323–6.

    PubMed  CAS  Google Scholar 

  38. Barat I, Andreasen F, Damsgaard EM. The consumption of drugs by 75-year-old individuals living in their own homes. Eur J Clin Pharmacol. 2000;56:501–9.

    Article  PubMed  CAS  Google Scholar 

  39. Kennedy J. Herb and supplement use in the US adult population. Clin Ther. 2005;27:1847–58.

    Article  PubMed  Google Scholar 

  40. Gardiner P, Graham RE, Legedza ATR, et al. Factors associated with dietary supplement use among prescription medication users. Arch Intern Med. 2006;166:1968–74.

    Article  PubMed  Google Scholar 

  41. Corcoran ME. Polypharmacy in the older patient with cancer. Cancer Control. 1997;4:419–28.

    PubMed  Google Scholar 

  42. Slone Epidemiology Center. Patterns of medication use in the United States: of medication use in the United States: Slone Epidemiology Center at Boston University. 2006. Available http://www.bu.edu/slone/SloneSurvey/sloneSurvey.htm. Accessed Sept 20 2009.

  43. Qato DM, Alexander GC, Conti RM, et al. Use of prescription and over-the counter medications and dietary supplements among older adults in the United States. JAMA. 2008;300:2867–78.

    Article  PubMed  CAS  Google Scholar 

  44. Di Maio M, Perrone F, Gallo C, et al. Supportive care in patients with advanced non-small-cell lung cancer. Br J Cancer. 2003;89:1013–21.

    Article  PubMed  Google Scholar 

  45. Gridelli C. The ELVIS trial: a phase III study of single-agent vinorelbine as first-line treatment in elderly patients with advanced NSCLC. Oncologist. 2001;6:4–7.

    Article  PubMed  CAS  Google Scholar 

  46. Gridelli C, Perrone F, Gallo C, et al. Chemotherapy for elderly patients with advanced non-small cell lung cancer: Multicenter Italian Lung cancer in the Elderly Study (MILES) phase III randomized trial. J Natl Cancer Inst. 2003;95:362–72.

    Article  PubMed  CAS  Google Scholar 

  47. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine for advanced non–small-cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 2003;21:3025–34.

    Article  PubMed  CAS  Google Scholar 

  48. Lichtman SM, Wildiers H, Chatelut E, et al. International Society of Geriatric Oncology (SIOG) Chemotherapy Taskforce: evaluation of chemotherapy in older patients-an analysis of the medical literature. J Clin Oncol. 2007;25:1832–43.

    Article  PubMed  CAS  Google Scholar 

  49. Jørgensen TL, Hallas J, Land LH, et al. Comorbidity and polypharmacy in elderly cancer patients: the significance on treatment outcome and tolerance. J Geriatr Oncol. 2010;1:87–102.

    Article  Google Scholar 

  50. Girre V, Arkoub H, Puts MTE. Potential drug interactions in elderly cancer patients. Crit Rev Oncol Hematol. 2011;78:220–6.

    Article  PubMed  CAS  Google Scholar 

  51. Riechelmann RP, Moreira F, Smaletz O, et al. Potential for drug interactions in hospitalized cancer patients. Cancer Chemother Pharmacol. 2005;56:286–90.

    Article  PubMed  Google Scholar 

  52. Blower P, de Wit R, Goodin S, et al. Drug-drug interactions in oncology: why are they important and can they be minimized? Crit Rev Oncol Hematol. 2005;55:117–42.

    Article  PubMed  Google Scholar 

  53. Singh BN, Malhotra BK. Effects of food on the clinical pharmacokinetics of anticancer agents: underlying mechanisms and implications for oral chemotherapy. Clin Pharmacokinet. 2004;43:1127–56.

    Article  PubMed  CAS  Google Scholar 

  54. Sparreboom A, Cox MC, Acharya MR, et al. Herbal remedies in the United States: potential adverse interactions with anticancer agents. J Clin Oncol. 2004;22:2489–503.

    Article  PubMed  CAS  Google Scholar 

  55. Damery S, Gratus C, Grivie R, et al. The use of herbal medicines by people with cancer: a cross-sectional survey. Br J Cancer. 2011;104:927–33.

    Article  PubMed  CAS  Google Scholar 

  56. Dergal JM, Gold JL, Laxer DA, et al. Potential interactions between herbal medicines and conventional drug therapies used by older adults attending a memory clinic. Drugs Aging. 2002;19:879–86.

    Article  PubMed  CAS  Google Scholar 

  57. Kuhlmann J, Muck W. Clinical-pharmacological strategies to assess drug interaction potential during drug development. Drug Saf. 2001;24:715–25.

    Article  PubMed  CAS  Google Scholar 

  58. Song X, Varkera H, Eichelbaumb M, et al. Treatment of lung cancer patients and concomitant use of drugs interacting with cytochrome P450 isoenzymes. Lung Cancer. 2011;74:103–11.

    Article  PubMed  Google Scholar 

  59. Lynch T, Price A. The effect of cytochrome P450 metabolism on drug response, interactions, and adverse effects. Am Fam Physician. 2007;76:348–51.

    Google Scholar 

  60. Goodin S. Oral chemotherapeutic agents: understanding mechanisms of action and drug interactions. Am J Health Syst Pharm. 2007;64:S15–24.

    Article  PubMed  CAS  Google Scholar 

  61. Dresser GK, Bailey DG, Leake BF, et al. Fruit juices inhibit organic anion transporting polypeptide-mediated uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther. 2002;71:11–20.

    Article  PubMed  CAS  Google Scholar 

  62. Christensen ML, Stewart CF, Crom WR. Evaluation of aminoglycoside disposition in patients previously treated with cisplatin. Ther Drug Monit. 1989;11:631–6.

    Article  PubMed  CAS  Google Scholar 

  63. Parimoo D, Jeffers S, Muggia FM. Severe neurotoxicity from vinorelbine-paclitaxel combinations. J Natl Cancer Inst. 1986;88:1079–80.

    Article  Google Scholar 

  64. Huizing MT, Giaccone G, van Warmerdan LJ, et al. Pharmacokinetics of paclitaxel and carboplatin in a dose-escalating and dose-sequencing study in patients with non-small-cell lung cancer. The European Cancer Centre. J Clin Oncol. 1997;15:317–29.

    PubMed  CAS  Google Scholar 

  65. Legrain S. Prescription to elderly patients: reducing underuse and adverse drug reactions and improving adherence. Bull Acad Natl Med. 2007;191:259–69.

    PubMed  Google Scholar 

  66. Beers MH, Ouslander JG, Rollingher I, et al. Explicit criteria for determining inappropriate medication use in nursing home residents: UCLA Division of Geriatric Medicine. Arch Intern Med. 1991;151:1825–32.

    Article  PubMed  CAS  Google Scholar 

  67. Fick DM, Cooper JW, Wade WE, et al. Updating the Beers criteria for potentially inappropriate medication use in older adults: results of a US consensus panel expert. Arch Intern Med. 2003;163:2716–24.

    Article  PubMed  Google Scholar 

  68. Vinks TH, Egberts TC, de Lange TM, et al. Pharmacist-based medication review reduces potential drug-related problems in the elderly: the SMOG controlled trial. Drugs Aging. 2009;26:123–33.

    Article  PubMed  CAS  Google Scholar 

  69. Hanlon JT, Schmader KE, Samsa GP, et al. A method for assessing drug therapy appropriateness. J Clin Epidemiol. 1992;45:1045–51.

    Article  PubMed  CAS  Google Scholar 

  70. Gallagher P, O’Mahony D. STOPP (Screening Tool of Older Person’s Potentially Inappropriate Prescriptions): application to acutely ill elderly patients and comparison with Beers’ criteria. Age Ageing. 2008;37:673–9.

    Article  PubMed  Google Scholar 

  71. Barry PJ, Gallagher P, Ryan C, et al. START (screening tool to alert doctors to the right treatment)an evidence-based screening tool to detect prescribing omissions in elderly patients. Age Ageing. 2007;36:632–8.

    Article  PubMed  CAS  Google Scholar 

  72. Davies SJC, Eayrs S, Pratt P, et al. Potential for drug interactions involving cytochromes P450 2D6 and 3A4 on general adult psychiatric and functional elderly psychiatric wards. Br J Clin Pharmacol. 2004;57:464–72.

    Article  PubMed  CAS  Google Scholar 

  73. Jansman F, Reyners AKL, van Roon EN, et al. Consensus-based evaluation of clinical significance and management of anticancer drug interactions. Clin Ther. 2011;33(3):305–14.

    Article  PubMed  CAS  Google Scholar 

  74. Medi-Span®. Indianapolis(IN): Medi-Span®. Master drug data base v2.5 (MDDB®). Available from: http://www.medispan.com/master-drug-database.aspx. Cited 29 Sep 2008.

  75. Cashman J, Wright J, Ring A. The treatment of comorbidities in older patients with metastatic cancer. Support Care Cancer. 2010;18:651–5.

    Article  PubMed  Google Scholar 

  76. Hanlon JT, Landsman PB, Cowan K, et al. Physician agreement with pharmacist suggested drug therapy changes for elderly out patients. Am J Health Syst Pharm. 1996;53:2735–7.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Onco-Geriatric Unit, Division of Medical Oncology, Vito Fazzi Hospital, Lecce, Italy

    Silvana Leo MD

  2. Emeritus Head of Oncogeriatrics, Department of Pharmacology, School of Clinical Pharmacology, University of Milan, Milan, Italy

    Dario Cova MD

  3. Division of Medical Oncology, S.G. Moscati Hospital, Avellino, Italy

    Antonio Rossi MD

  4. Department of Oncology, Sanremo Hospital – ASL 1 Imperiese, Via G. Borea 56 – 18038, Sanremo (IM), Italy

    Lazzaro Repetto MD, PhD

Authors
  1. Silvana Leo MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Dario Cova MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Rossi MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Lazzaro Repetto MD, PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lazzaro Repetto MD, PhD .

Editor information

Editors and Affiliations

  1. , Department of Oncology/Hematology, S.G. Moscati Hospital, Contrada Amoretta, Avellino, 83100, Italy

    Cesare Gridelli

  2. St Helens Teaching Hospital, University of Liverpool, Marshalls Cross Road, St Helens, WA9 3DA, United Kingdom

    Riccardo A Audisio

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer-Verlag London

About this chapter

Cite this chapter

Leo, S., Cova, D., Rossi, A., Repetto, L. (2013). Drug Interactions and Polypharmacy. In: Gridelli, C., Audisio, R. (eds) Management of Lung Cancer in Older People. Springer, London. https://doi.org/10.1007/978-0-85729-793-8_6

Download citation

  • DOI: https://doi.org/10.1007/978-0-85729-793-8_6

  • Published:

  • Publisher Name: Springer, London

  • Print ISBN: 978-0-85729-792-1

  • Online ISBN: 978-0-85729-793-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation